BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung CancerDr. James Bond of Surrey Memorial Hospital to act as Principal Investigator - Biomark Diagnostics

News

September 10, 2015

BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer

Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator

BioMark Diagnostics Inc.

BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.

BioMark Diagnostics to Conduct Validation Studies (PDF)

———————————————

Share this post:

Categories

Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.

CSE: BUX
OTC: BMKDF
FSE: 20B

More Information

Investors

Related articles ...

biomark-press-release

News

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN

BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify

October 1, 2024

biomark-press-release

News

BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection

BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for

September 11, 2024

biomark-press-release

News

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment Conference In New York

Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment

September 1, 2024

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report August 2024

Form 7 Monthly Progress Report Sept 2024 Name of Listed Issuer: Trading Symbol: Number of

September 1, 2024

biomark-progress-report

Articles and Information

Form 7 Monthly Progress Report July 2024

Form 7 Monthly Progress Report July 2024 Name of Listed Issuer: Trading Symbol: Number of

August 4, 2024

1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2

Pages

Latest Posts

Site Policies

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.